Detailed dose evidence documented for Liraglutide in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
The entries summarize the cited US FDA labels for the named products and their distinct approved indications.
Victoza: Initiate 0.6 mg SC daily × 1 wk, then 1.2 mg daily; may increase to 1.8 mg daily if additional glycemic control needed.
Saxenda: Initiate 0.6 mg SC daily, titrate weekly (0.6 mg increments) to 3.0 mg daily maintenance. Not interchangeable with Victoza.
Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
Doses up to 3.0 mg daily in weight management trials (Saxenda).
No studied regimen exceeds 3.0 mg daily.
Not established
What is not established
Efficacy for weight management without lifestyle intervention.
Long-term (≥5 year) weight maintenance.
Effectiveness of generic liraglutide bioequivalence versus reference product in clinical outcomes (approved via ANDA pathway based on pharmacokinetics).